Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4589-4593

  Saleh Mghir, Azzam ^a,b   Muller Serieys, Claudette ^c   Dinh, Aurélien ^a,b   Massias, Laurent ^c   Crémieux, Anne Claude ^a,b  

^a RAYMOND POINCARÉ HOSPITAL   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; RIFAMPICIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; IN VIVO CULTURE; INFECTIOUS ARTHRITIS; JOINT PROSTHESIS; KNEE ARTHROPLASTY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROSTHESIS INFECTION; SILICONE PROSTHESIS;

ANIMALS; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; KNEE PROSTHESIS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PROSTHESIS-RELATED INFECTIONS; RABBITS; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 80052867042     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00675-11     Document Type: Article

References (23)

1. Arbeit, R. D., D. Maki, F. P. Tally, E. Campanero, B. I. Eisenstein, and the Daptomycin 98-01 and 99-01 Investigators. 2004. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38:1673-1681.
2. Belmatoug, N., et al. 1996. A new model of experimental prosthetic joint infection due to methicillin-resistant Staphylococcus aureus: a microbiologic, histopathologic and magnetic resonance characterization. J. Infect. Dis. 174: 414-417.
3. Boucher, H. W., and G. Sakoulas. 2007. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin. Infect. Dis. 45:601-608.
4. 14C]sparfloxacin in experimental Staphylococcus aureus joint prosthesis infection. Antimicrob. Agents Chemother. 40:2111-2116.
5. Crémieux, A. C., and C. Carbon. 1997. Experimental model of bone and prosthetic joint infections. Clin. Infect. Dis. 25:1295-1302.
6. Darouiche, R. O. 2004. Treatment of infections associated with surgical implants. N. Engl. J. Med. 350:1422-1429.
7. Del Pozo, J. L., and R. Patel. 2009. Infection associated with prosthetic joints. N. Engl. J. Med. 361:787-794.
8. Dvorchik, B. H., D. Brazier, M. F. DeBruin, and R. D. Arbeit. 2003. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. 47: 1318-1323.
9. Garrigós, C., et al. 2010. Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign- body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 54:5251-5256.
10. John, A. K., et al. 2009. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob. Agents Chemother. 53:2719-2724.
11. Lefebvre, M., et al. 2010. Efficacy of daptomycin combined with rifampin for the treatment of experimental MRSA acute osteomyelitis. Int. J. Antimicrob. Agents 36:542-544.
12. Liu, C., et al. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 52:285-292.
13. Moise, P. A., D. North, J. N. Steenbergen, and G. Sakoulas. 2009. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect. Dis. 9:617-624.
14. Murillo, O., et al. 2009. Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillinresistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:4252-4257.
15. Rouse, M. S., et al. 2006. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J. Antimicrob. Chemother. 57:301-305.
16. 14C]teicoplanin in experimental Staphylococcus aureus joint prosthesis infection. Antimicrob. Agents Chemother. 42:2830-2835.
17. Saleh-Mghir, A., et al. 2002. Combination of synercid and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection. Antimicrob. Agents Chemother. 46:1122-1124.
18. Steckelberg, J. M., and D. R. Osmon. 2000. Prosthetic joint infections, p. 173-209. In F. A. Waldvogel and A. L. Bisno (ed.), Infections associated with indwelling medical devices, 3rd ed. ASM Press, Washington, DC.
19. van Hal, S. J., D. L. Paterson, and I. B. Gosbell. 2011. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient - a review of the literature. Eur. J. Clin. Microbiol. Infect. Dis. 30:603-610.
20. Vaudaux, P., et al. 2003. Comparative efficacy of daptomycin and vancomycin in the therapy of foreign body infection due to Staphylococcus aureus. J. Antimicrob. Chemother. 52:89-95. (Pubitemid 36850091)
21. Yang, S. J., et al. 2010. Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob. Agents Chemother. 8:3079-3085.
22. Yang, S. J., et al. 2010. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob. Agents Chemother. 54:3161-3169.
23. Zimmerli, W., A. Trampuz, and P. E. Ochsner. 2004. Prosthetic-joint infections. N. Engl. J. Med. 351:1645-1654.